{"schema_version":"1","generated_at":"2026-10-29T02:40:04.289Z","data_as_of":null,"url":"https://www.findmykol.com/kol/brittany-ragon","json_url":"https://www.findmykol.com/kol/brittany-ragon/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"brittany-ragon","name":"Brittany Ragon","credential":"MD","specialty":"Hematology","specialty_raw":"Hematology","therapeutic_area":"Hematology","therapeutic_areas":["Hematology"],"institution":"Levine Cancer Institute","institution_url":"https://www.findmykol.com/institution/levine-cancer-institute","city":"Charlotte","state":"NC","region":{"label":"Southeast","url":"https://www.findmykol.com/region/southeast"}},"identifiers":{"npi":"1598057986","orcid":"0000-0002-2460-0698","openalex":"A5042992484"},"summary":"Brittany Ragon is a Hematology physician affiliated with Levine Cancer Institute. OpenAlex indexes 91 publications with 665 citations (h-index 13); ClinicalTrials.gov lists 1 registered study matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Hematology"]},"scholarship":{"works_count":91,"cited_by_count":665,"h_index":13,"latest_activity_year":2025,"source":"works"},"trials":{"count":1,"shown":1,"withheld":0,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT06580106","title":"Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML","status":"RECRUITING","role":"Overall official","sponsor":"Wake Forest University Health Sciences","source_url":"https://clinicaltrials.gov/study/NCT06580106","trial_url":"https://www.findmykol.com/trial/NCT06580106"}],"source":"trials"},"payments":{"company_count":7,"program_years":{"first":2021,"last":null},"rows_total":11,"shown":3,"withheld":8,"rows":[{"payer":"Syndax Pharmaceuticals, Inc.","program_year":2025,"amount_usd":11529.38,"payment_count":10,"source_url":"https://openpaymentsdata.cms.gov/search?query=1598057986"},{"payer":"Astellas Pharma US Inc","program_year":2024,"amount_usd":153.98,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1598057986"},{"payer":"JAZZ PHARMACEUTICALS INC.","program_year":2024,"amount_usd":143.43,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1598057986"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1598057986","source":"payments"},"prescribing":{"data_year":2024,"areas_total":6,"areas_shown":3,"areas":[{"area":"Cancer & immunology","share_pct":35.7,"classes_total":4,"classes":[{"class":"Kinase inhibitor","setting":"prescribed","share_pct":16.9,"drugs":[{"name":"Tasigna","share_pct":61.9},{"name":"Sprycel","share_pct":38.1}],"max_beneficiaries":null},{"class":"Calcineurin inhibitor","setting":"prescribed","share_pct":6.8,"drugs":[{"name":"Cyclosporine Modified","share_pct":100}],"max_beneficiaries":null}]},{"area":"Dermatology","share_pct":23.7,"classes_total":1,"classes":[{"class":"Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor","setting":"prescribed","share_pct":23.7,"drugs":[{"name":"Acyclovir","share_pct":100}],"max_beneficiaries":14}]},{"area":"Anti-infectives","share_pct":22.5,"classes_total":2,"classes":[{"class":"Fluoroquinolone Antibacterial","setting":"prescribed","share_pct":17.3,"drugs":[{"name":"Levofloxacin","share_pct":100}],"max_beneficiaries":null},{"class":"Azole Antifungal","setting":"prescribed","share_pct":5.2,"drugs":[{"name":"Fluconazole","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"facility","data_year":2024,"office_pct":0,"facility_pct":100},"source":"medicare"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Results from paradigm - a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia","year":2025,"journal":"Blood","source_url":"https://doi.org/10.1182/blood-2025-6","status":"verified"},{"title":"Up-front alternative donor HCT in severe aplastic anemia: gaps and opportunities to translate evidence into practice","year":2025,"journal":"Blood Advances","source_url":"https://doi.org/10.1182/bloodadvances.2024015405","status":"verified"},{"title":"Results of the Phase 1B study of pegargiminase (ADI-PEG 20) in combination with AZA-VEN in newly diagnosed high-risk AML patients not candidates for intensive chemotherapy","year":2025,"journal":"Blood","source_url":"https://doi.org/10.1182/blood-2025-1650","status":"verified"},{"title":"Defining the clinical characteristics and outcomes of adult patients (pts) with 11q23/KMT2A-rearranged Acute Myeloid Leukemia (AML): An analysis from the MARROW consortium","year":2025,"journal":"Blood","source_url":"https://doi.org/10.1182/blood-2025-292","status":"verified"},{"title":"A multicenter real-world study on response and survival in older patients with acute myeloid leukemia treated with intensive chemotherapy versus VEN/HMA by 2022 and 2024 ELN risk stratifications: An analysis from the MARROW consortium","year":2025,"journal":"Blood","source_url":"https://doi.org/10.1182/blood-2025-5157","status":"verified"}],"source":"works"},"contact":{"address_1":"1021 MOREHEAD MEDICAL DR","address_2":"STE A","city":"Charlotte","state":"NC","zip":"282042990","phone":"980-442-2000","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1598057986","source":"identity"},"similar":[{"name":"Peter Voorhees","slug":"peter-voorhees","institution":"Levine Cancer Institute","specialty":"Hematology","url":"https://www.findmykol.com/kol/peter-voorhees","json_url":"https://www.findmykol.com/kol/peter-voorhees/profile.json"},{"name":"Benjamin Moeller","slug":"benjamin-moeller","institution":"Levine Cancer Institute","specialty":"Radiation Oncology","url":"https://www.findmykol.com/kol/benjamin-moeller","json_url":"https://www.findmykol.com/kol/benjamin-moeller/profile.json"},{"name":"Jubilee Brown","slug":"jubilee-brown","institution":"Levine Cancer Institute","specialty":"Gynecologic Oncology","url":"https://www.findmykol.com/kol/jubilee-brown","json_url":"https://www.findmykol.com/kol/jubilee-brown/profile.json"},{"name":"Robert Naumann","slug":"robert-naumann","institution":"Levine Cancer Institute","specialty":"Gynecologic Oncology","url":"https://www.findmykol.com/kol/robert-naumann","json_url":"https://www.findmykol.com/kol/robert-naumann/profile.json"},{"name":"Joseph Antin","slug":"joseph-antin","institution":"Harvard University","specialty":"Hematology","url":"https://www.findmykol.com/kol/joseph-antin","json_url":"https://www.findmykol.com/kol/joseph-antin/profile.json"},{"name":"Scott Kaufmann","slug":"scott-kaufmann","institution":"Mayo Clinic College of Medicine","specialty":"Hematology","url":"https://www.findmykol.com/kol/scott-kaufmann","json_url":"https://www.findmykol.com/kol/scott-kaufmann/profile.json"},{"name":"Jeffrey Miller","slug":"jeffrey-miller","institution":"University of Minnesota Medical School","specialty":"Hematology","url":"https://www.findmykol.com/kol/jeffrey-miller","json_url":"https://www.findmykol.com/kol/jeffrey-miller/profile.json"},{"name":"Ruben Mesa","slug":"ruben-mesa","institution":"Atrium Health Wake Forest Baptist Comprehensive Cancer Center","specialty":"Hematology","url":"https://www.findmykol.com/kol/ruben-mesa","json_url":"https://www.findmykol.com/kol/ruben-mesa/profile.json"}],"coverage":{"note":"A basic record from the physician directory. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":8,"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2024-07-15","collected_at":"2026-10-27T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024}},"methodology_url":"https://www.findmykol.com/about#methodology"}